Early Intervention with Adalimumab May Contribute to Favorable Clinical Efficacy in Patients with Crohn's Disease

Publisher： Karger

E-ISSN： 1421-9867|90|2|130-136

ISSN： 0012-2823

Source： Digestion, Vol.90, Iss.2, 2014-10, pp. : 130-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease

By Riis Åse   Martinsen Tom C.   Waldum Helge L.   Fossmark Reidar  

Scandinavian Journal of Gastroenterology, Vol. 47, Iss. 6, 2012-06 ,pp. : 649-657

Informa Healthcare

Access to resources Recommend Favorite

Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease

By  

Digestion, Vol. 81, Iss. 2, 2010-01 ,pp. : 78-85

Karger

Access to resources Recommend Favorite

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab

By  

Case Reports in Gastroenterology, Vol. 10, Iss. 2, 2016-06 ,pp. : 283-291

Karger

Access to resources Recommend Favorite

Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells

By Dige Anders   Hvas Christian Lodberg   Deleuran Bent   Kelsen Jens   Bendix-Struve Mia   Dahlerup Jens Frederik   Agnholt Jørgen  

Scandinavian Journal of Gastroenterology, Vol. 46, Iss. 10, 2011-10 ,pp. : 1206-1214

Informa Healthcare

Access to resources Recommend Favorite

Crohn's disease diagnosis during adalimumab treatment

By Fernández Salazar Luis   Barrio Andrés Jesús   González Hernández José Manuel  

Scandinavian Journal of Gastroenterology, Vol. 48, Iss. 2, 2013-02 ,pp. : 254-255

Informa Healthcare

Access to resources Recommend Favorite